Development and validation of a targeted gene sequencing panel for application to disparate cancers.

McCabe, Mark J; Gauthier, Marie-Emilie A; Chan, Chia-Ling; Thompson, Tanya J; De Sousa, Sunita M C; Puttick, Clare; Grady, John P; Gayevskiy, Velimir; Tao, Jiang; Ying, Kevin; Cipponi, Arcadi; Deng, Niantao; Swarbrick, Alex; Thomas, Melissa L; Lord, Reginald V; Johns, Amber L; Kohonen-Corish, Maija; O'Toole, Sandra A; Clark, Jonathan; Müller, Simon A.; ... (2019). Development and validation of a targeted gene sequencing panel for application to disparate cancers. Scientific reports, 9(1), p. 17052. Springer Nature 10.1038/s41598-019-52000-3

[img]
Preview
Text
s41598-019-52000-3.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (3MB) | Preview

Next generation sequencing has revolutionised genomic studies of cancer, having facilitated the development of precision oncology treatments based on a tumour's molecular profile. We aimed to develop a targeted gene sequencing panel for application to disparate cancer types with particular focus on tumours of the head and neck, plus test for utility in liquid biopsy. The final panel designed through Roche/Nimblegen combined 451 cancer-associated genes (2.01 Mb target region). 136 patient DNA samples were collected for performance and application testing. Panel sensitivity and precision were measured using well-characterised DNA controls (n = 47), and specificity by Sanger sequencing of the Aryl Hydrocarbon Receptor Interacting Protein (AIP) gene in 89 patients. Assessment of liquid biopsy application employed a pool of synthetic circulating tumour DNA (ctDNA). Library preparation and sequencing were conducted on Illumina-based platforms prior to analysis with our accredited (ISO15189) bioinformatics pipeline. We achieved a mean coverage of 395x, with sensitivity and specificity of >99% and precision of >97%. Liquid biopsy revealed detection to 1.25% variant allele frequency. Application to head and neck tumours/cancers resulted in detection of mutations aligned to published databases. In conclusion, we have developed an analytically-validated panel for application to cancers of disparate types with utility in liquid biopsy.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Ear, Nose and Throat Disorders (ENT)

UniBE Contributor:

Müller, Simon Andreas

Subjects:

600 Technology > 610 Medicine & health

ISSN:

2045-2322

Publisher:

Springer Nature

Language:

English

Submitter:

Stefan Weder

Date Deposited:

22 Jan 2020 10:30

Last Modified:

26 Jan 2020 02:49

Publisher DOI:

10.1038/s41598-019-52000-3

PubMed ID:

31745186

BORIS DOI:

10.7892/boris.137962

URI:

https://boris.unibe.ch/id/eprint/137962

Actions (login required)

Edit item Edit item
Provide Feedback